- Home
- Products
- Customized ADCs
- IL2RA
- Anti-IL2RA (Inolimomab)-MC-MMAF ADC
Anti-IL2RA (Inolimomab)-MC-MMAF ADC (CAT#: ADC-W-1360)
This ADC product is comprised of an anti-IL2RA monoclonal antibody conjugated via a MC linker to MMAF. The MMAF is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, MMAF binds to tubulins, interrupts microtubule dynamics, and subsequently, induces cell death.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- IL2RA
- Alternative Names
- IL2RA; interleukin 2 receptor, alpha; IL2R; interleukin-2 receptor subunit alpha; CD25; p55; IL2-RA; IL-2-RA; TAC antigen; IL-2R subunit alpha; IL-2 receptor subunit alpha; TCGFR; IDDM10;
- Target Entrez Gene ID
- 3559
- Target UniProt ID
- P01589
- Overview
- The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains (IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternately-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown. Mutations in this gene are associated with interleukin 2 receptor alpha deficiency
- Overview
- Humanized Anti-IL2RA IgG1-kappa antibody, Inolimomab
- Generic name
- Inolimomab
- Host animal
- Mouse
- Name
- MC (maleimidocaproyl)
- Description
- Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to occur after internalization of the ADC via antigen-mediated endocytosis and delivery to lysosomal compartment, where the antibody is degraded to the level of amino acids through intracellular proteolytic degradation.
- Name
- MMAF
- Description
- Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-IL13 (Lebrikizumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-1307)
- Anti-ITGA2B (Abciximab)-SPDB-DM4 ADC (CAT#: ADC-W-1461)
- Anti-ERBB2 (Trastuzumab)-VC-DUBA ADC (CAT#: ADC-W-514)
- Anti-SLAMF7 (Elotuzumab)-SPDB-DM4 ADC (CAT#: ADC-W-1761)
- Anti-NRP1 (Vesencumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1680)
- Anti-TNFRSF17 (clone CA8 J9M2)-VC-MMAE ADC (CAT#: ADC-W-277)
- Anti-CD28 (lumretuzumab)-SMCC-DM1 ADC (CAT#: ADC-W-2276)
- Anti-HCMV (Regavirumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2105)
- Anti-SOST (Blosozumab)-SMCC-DM1 ADC (CAT#: ADC-W-1766)
- Anti-CD22 (clone RFB4)-Mc-VC-PABC-MMAF ADC (CAT#: ADC-W-191)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-1360. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-1364 | Anti-IL2RA (Basiliximab)-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2'-Deacetyl-N2'-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-1369 | Anti-IL2RA (Basiliximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-1367 | Anti-IL2RA (Basiliximab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-1372 | Anti-IL2RA (Daclizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-1366 | Anti-IL2RA (Basiliximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2612 | Anti-MS4A1 (Rituximab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-537 | Anti-TPBG-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-322 | Anti-CD19 (clone hBU12)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-515 | Anti-EGFR (ABT-806)-Mc-MMAF ADC | Mc (maleimidocaproyl) | MMAF (Monomethyl auristatin F) |
| ADC-W-518 | Anti-TM4SF1 ( clone 2A7A)-Mc-LP2 ADC | Mc (maleimidocaproyl) | LP2 (chemical name mc-3377) |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2600 | Anti-GPNMB (Glembatumumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2606 | Anti-ITGB3 (Tadocizumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2544 | Anti-CD44 (Bivatuzumab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2622 | Anti-NCAM1 (Lorvotuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
| ADC-W-2556 | Anti-CD79B (Polatuzumab )-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
